CRISPR Therapeutics (CRSP): Fair Value After 65% Drop?

Date: August 20, 2025

CRISPR Therapeutics (NASDAQ:CRSP) has seen its shares slide approximately 65% over the past five years, wiping out billions in market value. The stock now trades at a price-to-book (P/B) ratio of 2.6x, a level that sits close to the biotech industry average of 2.4x but well below the peer group mean of 7.3x. On the surface, this suggests investors are assigning a modest premium to the company’s balance sheet—but not the rich multiples enjoyed by some better-funded rivals. The question is whether today’s price already reflects the long-term setbacks, or if the pipeline promise still has meaningful upside.

Pipeline Progress: CTX112 and the CAR-T Race

CRISPR Therapeutics’ lead allogeneic CAR-T candidate, CTX112, is currently in Phase 1 clinical trials targeting relapsed/refractory B-cell malignancies and autoimmune diseases. The therapy aims to be an “off-the-shelf” alternative to autologous CAR-Ts, which are costly and time-consuming to manufacture. Early data from the dose-escalation portion of the study has shown a 65% overall response rate (ORR) among evaluable patients with large B-cell lymphoma, according to a company update released in July 2025. While the sample size is small, the response rate is competitive with existing approved CAR-Ts, and the safety profile so far appears manageable.

The company is also exploring CTX112 in systemic lupus erythematosus (SLE), a high-value autoimmune indication. If successful, this could open a much larger addressable market than oncology alone. The global CAR-T therapy market is projected to reach $60 billion by 2030, per Grand View Research, and allogeneic platforms could capture a significant share if durability and safety are confirmed.

Valuation Check: P/B Provides a Floor, But Not a Ceiling

The P/B multiple is a useful anchor for CRISPR Therapeutics because the company remains in a pre-revenue, R&D-intensive phase. Its book value of roughly $2.1 billion (as of Q2 2025) is composed largely of cash, cash equivalents, and marketable securities. At a market cap of about $5.5 billion, the stock trades at 2.6x book—a 10% premium to the biotech sector median of 2.4x, but a 65% discount to the peer group average of 7.3x (which includes highly capitalized names like Vertex Pharmaceuticals and CRISPR’s own collaboration partner, Bayer).

This suggests that the market is not pricing in a full-blown blockbuster success for CTX112 yet. If the drug achieves a 30% peak penetration in the non-Hodgkin lymphoma market alone, with a $300,000 price per patient, the net present value of the program could exceed $8 billion under conservative discount rates. Current valuation leaves room for upside, but also incorporates significant clinical and regulatory risk.

Why the Stock Has Lagged: Execution and Competitor Threats

CRISPR Therapeutics’ 14.4% decline over the past 12 months underperforms the broader biotech index (IBB), which is roughly flat. The main headwinds include: (1) slower-than-expected enrollment in the CTX112 Phase 1 due to a competitive landscape—approved CAR-Ts from Kite/Gilead, Novartis, and Bristol Myers Squibb have already captured the relapsed/refractory market; (2) a capital allocation shift by the company—it raised $400 million in a convertible note offering in early 2025, diluting existing shareholders; and (3) lingering concerns about gene-editing off-target effects, which could trigger regulatory holds.

Furthermore, competitors like Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) are advancing their own allogeneic platforms, and the race to get an “off-the-shelf” product to market is intensifying. CRISPR Therapeutics’ partnership with Vertex (for exa-cel in sickle cell disease) provides a steady cash flow stream, but the royalty revenue from exa-cel is only $0.035 per unit of exa-cel sold, according to the Vertex 2024 annual report—a modest tailwind.

The Bottom Line: A Balanced Bet on Gene Editing

CRISPR Therapeutics stock is not a clear bargain, but it is not a bubble either. The current P/B multiple suggests that much of the pipeline risk is already priced in. For the stock to re-rate, investors will need to see positive Phase 2 data for CTX112 in 2026, resolution of manufacturing challenges, and evidence that the allogeneic CAR-T can compete on efficacy and durability with autologous products. On the flip side, any clinical setback or regulatory delay could push the stock back toward its book value.

What makes CRISPR Therapeutics unique is its combination of a strong balance sheet, a validated gene-editing platform (Cas9), and a first-mover advantage in allogeneic CAR-T. The stock is a high-risk/high-reward play that may appeal to investors with a long time horizon and a tolerance for volatility. For those who believe in the pipeline, the current price may offer an entry point; for others, waiting for clearer catalysts is prudent.

This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.